@article{WolterHanselmannPattschulletal.2017,
  author    = {Wolter, Patrick and Hanselmann, Steffen and Pattschull, Grit and Schruf, Eva and Gaubatz, Stefan},
  title     = {Central spindle proteins and mitotic kinesins are direct transcriptional targets of MuvB, B-MYB and FOXM1 in breast cancer cell lines and are potential targets for therapy},
  series = {Oncotarget},
  volume    = {8},
  journal   = {Oncotarget},
  number    = {7},
  doi       = {10.18632/oncotarget.14466},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-171851},
  pages     = {11160-11172},
  year      = {2017},
  abstract  = {The MuvB multiprotein complex, together with B-MYB and FOXM1 (MMB-FOXM1), plays an essential role in cell cycle progression by regulating the transcription of genes required for mitosis and cytokinesis. In many tumors, B-MYB and FOXM1 are overexpressed as part of the proliferation signature. However, the transcriptional targets that are important for oncogenesis have not been identified. Given that mitotic kinesins are highly expressed in cancer cells and that selected kinesins have been reported as target genes of MMB-FOXM1, we sought to determine which mitotic kinesins are directly regulated by MMB-FOXM1. We demonstrate that six mitotic kinesins and two microtubule-associated non-motor proteins (MAPs) CEP55 and PRC1 are direct transcriptional targets of MuvB, B-MYB and FOXM1 in breast cancer cells. Suppression of KIF23 and PRC1 strongly suppressed proliferation of MDA-MB-231 cells. The set of MMB-FOXM1 regulated kinesins genes and 4 additional kinesins which we referred to as the mitotic kinesin signature (MKS) is linked to poor outcome in breast cancer patients. Thus, mitotic kinesins could be used as prognostic biomarker and could be potential therapeutic targets for the treatment of breast cancer.},
  language  = {en}
}
@article{JungwirthYuMoustafaetal.2019,
  author    = {Jungwirth, Gerhard and Yu, Tao and Moustafa, Mahmoud and Rapp, Carmen and Warta, Rolf and Jungk, Christine and Sahm, Felix and Dettling, Steffen and Zweckberger, Klaus and Lamszus, Katrin and Senft, Christian and Loehr, Mario and Keßler, Almuth F. and Ketter, Ralf and Westphal, Manfred and Debus, Juergen and von Deimling, Andreas and Simon, Matthias and Unterberg, Andreas and Abdollahi, Amir and Herold-Mende, Christel},
  title     = {Identification of KIF11 as a Novel Target in Meningioma},
  series = {Cancers},
  volume    = {11},
  journal   = {Cancers},
  number    = {4},
  issn      = {2072-6694},
  doi       = {10.3390/cancers11040545},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-197402},
  year      = {2019},
  abstract  = {Kinesins play an important role in many physiological functions including intracellular vesicle transport and mitosis. The emerging role of kinesins in different cancers led us to investigate the expression and functional role of kinesins in meningioma. Therefore, we re-analyzed our previous microarray dataset of benign, atypical, and anaplastic meningiomas (n = 62) and got evidence for differential expression of five kinesins (KIFC1, KIF4A, KIF11, KIF14 and KIF20A). Further validation in an extended study sample (n = 208) revealed a significant upregulation of these genes in WHO°I to °III meningiomas (WHO°I n = 61, WHO°II n = 88, and WHO°III n = 59), which was most pronounced in clinically more aggressive tumors of the same WHO grade. Immunohistochemical staining confirmed a WHO grade-associated upregulated protein expression in meningioma tissues. Furthermore, high mRNA expression levels of KIFC1, KIF11, KIF14 and KIF20A were associated with shorter progression-free survival. On a functional level, knockdown of kinesins in Ben-Men-1 cells and in the newly established anaplastic meningioma cell line NCH93 resulted in a significantly inhibited tumor cell proliferation upon siRNA-mediated downregulation of KIF11 in both cell lines by up to 95\% and 71\%, respectively. Taken together, in this study we were able to identify the prognostic and functional role of several kinesin family members of which KIF11 exhibits the most promising properties as a novel prognostic marker and therapeutic target, which may offer new treatment options for aggressive meningiomas.},
  language  = {en}
}